---
title: "Restart Life Sciences Provides Performance and Revenue Trend Update on Newly Acquired Superseed Cereals and Oatmeal Brand Portfolio | NMLSF Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/283640055.md"
description: "Restart Life Sciences Provides Performance and Revenue Trend Update on Newly Acquired Superseed Cereals and Oatmeal Brand Portfolio | NMLSF Stock News"
datetime: "2026-04-22T02:05:52.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/283640055.md)
  - [en](https://longbridge.com/en/news/283640055.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/283640055.md)
---

# Restart Life Sciences Provides Performance and Revenue Trend Update on Newly Acquired Superseed Cereals and Oatmeal Brand Portfolio | NMLSF Stock News

Restart Life Sciences Provides Performance and Revenue Trend Update on Newly Acquired Superseed Cereals and Oatmeal Brand Portfolio | NMLSF Stock News

### Related Stocks

- [RSLS.US](https://longbridge.com/en/quote/RSLS.US.md)
- [ATNF.US](https://longbridge.com/en/quote/ATNF.US.md)
- [SAVU.US](https://longbridge.com/en/quote/SAVU.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [HEAL.US](https://longbridge.com/en/quote/HEAL.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)

## Related News & Research

- [Genprex data shows gene therapy reverses hyperglycemia in T2D mice at ASGCT](https://longbridge.com/en/news/286414681.md)
- [Regenxbio's muscle disorder therapy meets main goal in late-stage study](https://longbridge.com/en/news/286406339.md)
- [US cancer clinics scramble to get experimental Revolution Medicines pancreatic cancer drug](https://longbridge.com/en/news/286394551.md)
- [Full Transcript: Cellectar Biosciences Q1 2026 Earnings Call](https://longbridge.com/en/news/286422585.md)
- [Analyst Reiterates Buy on Corbus, Maintains $38 Price Target on CRB-701 Oncology Potential](https://longbridge.com/en/news/286284525.md)